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Nanoparticles displaying native proteins are attractive for many applications, including vaccinology.
Virus-based nanoparticles are easily tailored by genetic means, commonly by inserting heterologous
sequences into surface-exposed loops. The strategy works well with short peptides but is incompatible with
the structures of most native proteins, except those with closely juxtaposed termini. Here we overcome this
constraint by splitting the capsid protein of hepatitis B virus, one of the most advanced and most
immunogenic display platforms, inside the insertion loop (SplitCore). The split parts, coreN and coreC,
efficiently form capsid-like particles (CLPs) in E. coli and so do numerous fusions to coreN and/or coreC of
differently structured proteins, including human disease related antigens of .300 amino acids in length.
These CLPs induced high-titer antibodies, including neutralizing ones, in mice. The concept was easily
expanded to triple-layer CLPs carrying reporter plus targeting domains, and should be applicable to
protein-based nanoparticle design in general.
V
iral capsids are natural self-assembling nanoparticles amenable to genetic modification, with diverse
applications in material science
1, 2 and biomedicine
3 including vaccinology
4. The icosahedral nucleo-
capsid of hepatits B virus (HBV) is particularly well characterized in the latter aspect
5. Authentic nucleo-
capsids are formed by 120 (triangulation number T54; diameter ,34 nm) or to a lesser extent 90 dimers (T53;
diameter ,30 nm)
6 of a single 183 amino acid (aa) core protein (HBc; reviewed in
7); its Nterminal ,140 aa are
required for assembly
8, 9, the capsid-internal C terminal domain (CTD) binds nucleic acids. In the largely
a-helicalfoldoftheassemblydomain
10–12,ahairpinformedbyhelicesa3anda4servesasdimerizationinterface
(Fig.1a);theresultingfour-helixbundlesprotrudefromthecapsidsurfaceasprominentspikes.Theexposedloop
connecting a3 and a4 is part of the immunodominant c/e1 B-cell epitope between aa 74–84 which evokes .90%
oftheanti-HBcresponseduringHBVinfection
13.HBcparticlesareexceptionallyimmunogenic,likelyduetothe
repetitivesurfacepresentationofBcellepitopes
14,thepresenceofpotentTcellepitopes,plustheirabilitytoactas
T cell independent antigen
15. These properties contribute to the potent immunogenicity enhancement experi-
enced by foreign sequences displayed on HBc CLPs, especially if inserted into the most surface-exposed, yet
sequence-internal, c/e1 loop; however, such insertions must not compromise assembly competence.
Display of small peptides in the c/e1 loop is well established
16, and HBc CLPs presenting a peptide from the
circumsporozoite protein (CSP) of the malaria agent Plasmodium falciparum have proven safe in a Phase I study
17;
results with CLPs presenting an influenza A virus peptide are soon to be expected (ClinicalTrials.gov Identifier:
NCT00819013). However, one or a few epitopes account neither for the genetic diversity and adaptability of
pathogens nor for immunological polymorphisms in vaccinees; furthermore, peptides wedged into the carrier
may adopt new, antigenically irrelevant structures
18. Displaying native whole proteins would overcome these
limitations
19 and provide new opportunities also for non-vaccine applications. Successful whole-protein display
has first been reported for terminal fusions to small bacteriophage l and T4 accessory proteins that bind to
preformed capsids
20, 21.However, due totheir complexity these systemshave notfound wide-spread application.
A much simpler access to protein-displaying particles was provided by our demonstration that HBc can present
the 238 aa green fluorescent protein (GFP)
22, as well as the outer surface protein C (OspC) of the Lyme disease
agent Borrelia burgdorferi (Bb)
23, with those CLPs inducing neutralizing antibodies
24. Both proteins are excep-
tional in that their closely juxtaposed termini
25, 26 fit naturally into the c/e1 acceptor sites. In contrast, proteins
with farther apart termini interfere with assembly, as exemplified by Bb OspA
27. Bridging the distance with long
connecting linkers was only partially effective, and although the mostly irregular multimers evoked protective
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28, structural heterogeneity and the unknown immuno-
genic potential of the linkers are undesirable for a vaccine.
Hence the conformational stress imposed on carrier and insert by
the two-sided fixation emerged as key problem. Opening one of the
two linkages should relieve this stress, as was corroborated by
enhancedCLPformationbyanHBc-OspAfusionuponsite-directed
cleavage via an engineered protease site
29. However, the extra
sequences and processing steps prompted us to seek a more general
solution, leading to the ‘‘SplitCore’’ concept (Fig. 1b).
As in some non-multimerizing proteins
30, fragment complemen-
tationoftheseparatelyexpressedNandCterminalparts(coreNand
coreC) of HBc split inside the c/e1 loop might yield CLP-forming
splitsubunits.ForeignsequencesfusedtocoreNand/orcoreCwould
beattachedtosuchCLPsviaoneendonlyandthuswithoutimposing
conformational stress, regardless of their structure (Fig. 1b, bottom
right). The data reported below demonstrate the validity of this con-
cept and suggest its applicability to protein-based nanoparticle scaf-
folds in general.
Results
Separately expressed coreN and coreC fragments assemble
efficiently into HBc-like CLPs. Efficient complementation
requires that the two fragments be expressed in near equimolar
amounts, with minimal non-specific aggregation. This was best
achieved by using bicistronic mRNAs (Fig. 1b). The original
constructs encoded coreN (aa 1–79) and coreC (aa 80–149 or 80–
183) in that order, each preceded by its own ribosome binding site
(RBS). Alternative functional designs included overlapping stop and
start codons (see Supplementary Fig. S2 online). For some fusion
proteins (e.g. Supplementary Fig. S7 online), reversing the cistron
order provided superior expression, likely due to differential start
codon accessibility
31. Their functionality further excluded that
read-through products comprising both fragments, as were
occasionally formed (e.g. Supplementary Fig. S2), were required as
association scaffolds.
Sucrose gradient sedimentation of cleared lysates from bacteria
expressing coreN plus coreC149 (SplitCore149) or coreC183
(SplitCore183) revealed cosedimentation (Fig. 2a) of two peptides
of the expected sizes into the particle-typical center fractions
32,i n
yieldsof10–15 mg/Lofculture.Complementationwascorroborated
by native agarose gel electrophoresis (NAGE) where particles
Figure 1 | StructuralrationaleoftheSplitCoreapproach. (a)SchemeoftheHBcassemblydomain(aa1–143),basedonx-raydata(pdb:1QGT
12).Inthe
dimer(thesecondmonomerisshowningrey),thea3(white)-a4(skyblue)hairpinsassociateintofour-helix-bundles;thec/e1epitopelocatestotheloop
connecting a3 and a4. Helices a1 and a2 are omitted for clarity; a5 and the sequence to position 140 (orange) mediate multimerization of 90 or 120
dimers into T53 and T54 CLPs; cryo EM reconstructions are from
34. The CTD (not shown) locates to the interior. (b) SplitCore concept. The HBc
sequencewassplitinsidec/e1 betweenP79 andA80viaartificial stopandstartcodons.Efficient co-expression inE.coliofcoreN (aa1–79)andcoreC(aa
80–149or 183)was achieved by bicistronic vectorswith the 39 cistron controlled by asecond ribosome binding site (RBS II), or via overlapping stopand
start codons (e.g. Supplementary Fig. 2c). If the separate coreN and coreC fragments maintained the ability to assemble into HBc-like particles (left
arrow), the resulting SplitCore CLPs would expose new termini on their surface, either of which could serve as one-sided, sterically unrestrained
attachment site (right arrow) for heterologous molecules (X, Y).
Figure 2 | Efficient assemblyof splitwild-typeHBc. (a)Co-sedimentation
in sucrose gradients of separately expressed coreN and coreC fragments
(indicated by the downward pointing arrows) into particle-typical
fractions. Cleared lysates from bacteria co-expressing coreN and
coreC183H6 were sedimented through sucrose gradients, and aliquots of
each fraction were analyzed by SDS-PAGE and Coomassie-Blue (CB)
staining; coreN plus coreC149H6 and constructs lacking the His-tag gave
comparable results. The somewhat lower than expected mobility of the
coreC183H6 fragment observed in these and all subsequent experiments
likely results fromthe higharginine-contentofthe CTD. (b)Nativeagarose
gel electrophoresis (NAGE). Aliquots from the center gradient fractions
were subjected to NAGE; particle-borne RNA was visualized by ethidium
bromide (EtBr), protein by CB. (c) Negative staining EM of SplitCore and
conventional HBc149_H6 CLPs. Additional structural and antigenic
properties of SplitCore are shown in Supplementary Figure S1 online.
www.nature.com/scientificreports
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8. Like contiguous HBc, the split 183 and
149 derivatives each produced a single band upon Coomassie Blue
staining; their slower mobility (Fig. 2b, bottom) likely relates to
changes in surface charge mediated by the new exposed termini.
HBc CLPs containing the CTD package bacterial RNA
8, 33 which
can be stained with ethidium bromide. The same was observed for
SplitCore183, proving integrity of the CLPs (Fig. 2b, top). Abundant
intact particles were also detected by negative staining EM (Fig. 2c).
Thesedatademonstrateefficientself-complementationofcoreNand
coreC with and without CTD into assembly-competent structures.
Splitting HBc in c/e1 preserves the global particle structure but
destroys the immunodominant epitope and subtly affects others.
By high-percentage NAGE and direct evaluation of electron
micrographs we observed an increased fraction of about 30–40%
vs. ,5% T53 particles for the SplitCore CLPs (see Supplementary
Fig.S1).Asinsertionsintoc/e1canexertasimilareffect
34,thesedata
confirm independently that there is structural cross-talk between
the spike tip and the C proximal multimerization sites
34.
Immunoblotting of NAGE gels (see Supplementary Fig. S1 online)
withmonoclonalantibodies(mAb’s)revealedacompletelossofc/e1
reactivity whereas reactivity with the particle-specific mAb’s 275
13
and 3120
35 was only slightly reduced. Hence SplitCore CLPs mimic
the structure of HBc though with subtle alterations in regions away
fromthespiketip.Theabsenceofc/e1reactivity wasalsoreflected in
a 15- to 80-fold reduced reactivity of SplitCore and SplitCore-GFP
CLPs (see below) with anti-HBc antibodies from human serum in
three widely used diagnostic anti-HBc assays (see Supplementary
Fig. S1 and Supplementary Protocols online).
SplitCore-CLPs can natively display GFP fused to either coreN or
coreC. Next we tested whether the SplitCore system is compatible
with native surface display of a heterologous protein. GFP is an ideal
model
22becausechromophoreformationdependsonnativefolding.
Constructs with GFP fused to either coreN or coreC were well
expressed, including from a stop/start vector (see Supplementary
Fig. S2 online), cosedimented in sucrose gradients, and ran as
distinct, green fluorescent bands in NAGE (see Supplementary
Fig. S2); similar results were obtained with the coreC149
constructs and with GFP replaced by the red fluorescent mCherry
(T.T.A. Nguyen and M. Nassal, unpublished results). Also Bb OspC
fused to coreN formed CLPs with comparable efficiency (see
Supplementary Fig. S3 online) as the previously described
contiguous chain construct
24; hence for such favorable structures
the SplitCore platform is as suited as conventional HBc.
SplitCore allows CLP presentation of an unfavorably structured
protein that prevents CLP formation in the conventional HBc
system. The extended structure of OspA (Fig. 3, and
Supplementary Fig. S4) is incompatible with efficient CLP
formation upon c/e1 insertion
28 (Fig. 3a, coreOspA183H6). In
contrast, OspA fused to either coreN or coreC, and thereby
exposing different parts of OspA (see below), efficiently formed
regular CLPs, as indicated by sedimentation (see Supplementary
Fig. S4 online) and EM (Fig. 2a, coreN-OspA183H6, OspA-
coreC183H6). Similar results were obtained with coreC149
constructs (data not shown).
For immunogenicity evaluation, the further purified (see Supple-
mentary Fig. S4 online) and endotoxin-depleted
36CLP preparations
were used to immunize mice as described
28 and Supplementary Information;
lipidated (Pam3-Cys) OspA (LipOspA), the active ingredient of the
commercial Lymerix vaccine in which the lipid acts as TLR agonist,
served as reference. While details will be reported elsewhere (A.
Walker, T. Stehle, R. Wallich, M. Simon and M. Nassal, manuscript
in preparation) the most pertinent results were: (i) both CLP pre-
parations, and OspA-coreC in particular, induced higher levels of
OspA-specific antibodies than LipOspA (Fig. 3b); (ii) in an estab-
lished mouse model of Lyme disease
37, passive transfer of the anti-
seratocoreN-OspA andLymerixprotected6of6and5of6animals,
respectively, from chronic Bb infection whereas only 1 of 6 mice was
protected by the OspA-coreC induced antibodies (Fig. 3c). This
result is rationalized by the location of the major neutralizing epi-
tope,LA2,intheCterminalpartofOspA
38whichissolvent-exposed
in coreN-OspA but not OspA-coreC CLPs (Fig. 3a); indeed, the
Figure 3 | Drastically enhanced CLP formation by SplitCore OspA fusions, and distinct immunological properties of SplitCore-OspA CLPs. (a) The
ectodomain (aa 18–273) of Bb OspA adopts an extended b-sheet structure, with N and C terminus .6 nm apart (see Supplementary Fig. S4a for more
details). Conventional insertion into c/e1 required very long linkers to generate soluble, though rarely regular particle forming, aggregates (left). In
contrast,SplitCorewithOspAfusedtoeithercoreNorcoreCefficientlyformedregularCLPs.Dependingonorientation,theneutralizingLA2epitope
38is
solvent-exposed, or buried. (b) SplitCore-OspA CLPs induce comparable if not higher anti-OspA antibody titers than the LipOspA Lymerix vaccine.
Groupsof 5 Balb/c mice each were immunized with 10 mg each of the indicated CLPs (endotoxin content ,50 EU/mg protein) or LipOspA on day 0,14,
18 and 49. anti-OspA titers (in mg/ml serum) in sera collected at day 22 and 57 are shown. (c) Protectivity against chronic Bb infection. The indicated
immuneseraweretransferredintoSCIDmice,andtheanimalswerechallengedwith10
4borreliae(strainZS7)each.Developmentofarthriticdiseasewas
monitoredover52days
28;animalsremainingsymptom-freewereconsideredprotectedfromchronicinfection.Thelowprotectivepotentialdespitehigh
overall anti-OspA titer of the OspA-coreC183 induced immune sera correlated with a 4- to 5-times lower content in LA2-equivalent antibodies
(A. Walker, T. Stehle, R. Wallich, M. M. Simon, and M. Nassal; manuscript in preparation).
www.nature.com/scientificreports
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shown). Thus the SplitCore system allows to deliberately direct anti-
bodies against a specific antigen region, with potentially relevant
consequences for protectivity.
SplitCore-CLPs can display near full-length P. falciparum CSP
and induce very high titer anti-CSP yet lower titer anti-HBc
antibodies. Next we tested the SplitCore system’s ability to display
an even larger protein, CSP, from Plasmodium falciparum. CSP
consists of ,400 aa (Fig. 4a), including an immunodominant
central repeat region with a variable number (,40) of repetitions
of NANP and fewer NVDP motifs
39. Two of the most advanced, yet
only modestly protective, malaria vaccine formulations are RTS,S
39
andICC-1132
17.RTS,ScomprisestheCterminalhalfofCSPwithout
the GPI anchor signal fused to the small HBV surface protein (HBs);
ICC-1132 features several of the central repeat motifs inserted into
HBcc/e1plustheCSPuniversalTcellepitopefusedtotheHBc149C
terminus. Beyond the much lower intrinsic immunogenicity of HBs
vs. HBc antigen
40, the lack in either vaccine of potentially important
epitopes in the N terminal CSP sequence
41 may limit their efficacy.
Here we fused the 319 aa CSP sequence from the well characterized
derivative CS27IVC
42 to coreN. A conventional c/e1 insertion
construct was completely insoluble, but the SplitCore versions
(with coreC149H6 and coreC183H6) efficiently formed CLPs (see
Supplementary Fig. S5 online); EM revealed abundant particles with
aregular inner and a more elaborate, often ninja-star-like outer shell
(Fig. 4c), consistent with the recently proposed extended rod-like
structure of CSP
41.
For immunogenicity testing further purified SplitCoreN-CSP149
CLPs (see Supplementary Fig. S5 online) were used to immunize
mice
43 and Supplementary Information; a conventional repeat peptide construct
(HBc149-NANP) analogous to ICC-1132 (Fig. 4b) served as ref-
erence (A. Walker, J. Billaud, D. Milich, M. Nassal; manuscript in
preparation). Either CLP induced very high titers of NANP peptide-
specific antibodies. When tested against recombinant CSP, the anti-
serainducedbytheCSP-presenting CLPsgaveevenstrongersignals,
likely owing to the presence of additional antibodies recognizing
non-NANP epitopes; in contrast, anti-HBc titers were 5- to 20-fold
lower. Hence SplitCore-CSP CLPs may overcome shortcomings of
both RTS,S and ICC-1132, warranting further investigation of their
protective potential.
Triple-layer fluorescent SplitCore CLPs exposing a targeting
domain. Next we evaluated the ability of SplitCore CLPs to
simultaneously present two different sequences per split subunit.
As a model for a heterodimeric insert, we chose split GFP because
of its known self-complementation ability when separated at various
sites
30. Furthermore, the GFP-internal new termini, if exposed,
might allow to add yet another protein shell around the HBc
scaffold (Fig. 5a); finally, GFP provides a conventient reporter to
monitor how such additional domains affect the properties of the
CLPs. A solubility-enhanced GFP variant was split in the loop
between b-strands 10 and 11 of the barrel structure
44 so as to
expose the splitting site to the solvent; GFPb1-10 was fused to
coreN, and GFPb11 to coreC. The resulting SplitCore-SplitGFP
(SC-SGFP) protein was well expressed in largely soluble,
particulate and fluorescent form (see Supplementary Fig. 6 online).
As a third domain, we fused the B1 immunoglobulin-binding
domain from protein G (GB1) to the GFPß11-coreC fragment
(Fig. 5). GB1 is relatively small (56 aa) but retains a high affinity
for immunoglobulins. The bipartite triple fusion termed SC-SGFP-
GB1 was highly expressed (,40 mg soluble protein/L culture), and
efficiently formed fluorescent CLPs according to sedimentation,
NAGE analysis and EM (Fig. 5b–d). Immunoglobulin binding was
demonstratedbyindirectimmunofluorescencemicroscopy(Fig.5e),
where the CLPs generated a very similar, primary antibody-depend-
ent staining pattern asan Alexa-488 conjugated secondary antibody.
SC-SGFP-GB1 CLPs could also substitute for dye-labeled secondary
antibody in fluorescent Western blots with comparable sensitivity
(Fig. 5f), and they detected antibody-decorated cells in flow cytome-
try (A. Walker, PhD thesis, University of Freiburg, 2008).
The small GB1 domain does not push the system to its limits. We
have successfully generated fluorescent SplitCore CLPs with OspC
fused to coreN-GFPb1-10, or to GFPb11-coreC; and with OspA
Figure 4 | SplitCore-CLPs can display the entire P. falciparum circumsporozoite protein (CSP) ectodomain. (a) General organization of CSP. CSPs are
,400 aa in length, with an N terminal signal sequence and a C terminal glycosylphosphatidyl-inositol (GPI) anchor signal. The central region contains a
variable number of NANP and fewer NVDP repeats (,40 total), the C proximal region a thrombospondin type-1 repeat (TSR) including a universal
T cell epitope (UTC). Experimental vaccineICC-1132 carries a few of the repeats inserted into c/e1 of HBc, plustheUTC fused tothe C terminus
17; vaccine
RTS,S comprises the C terminal half of CSP except the GPI signal, fused to the small surface antigen (HBs) of HBV
39.C S 2 7 I V
42, based on the T4 isolate/
Thailand (Genbank accession no. M19752), lacks the terminal signals and 14 NANP repeats. (b) Schematic structures of SplitCoreN-CSP-149, carrying
the entire CS27IV sequence, and HBc149-NANP. (c) CLP formation by SplitCoreN-CSP-149 and -183 revealed by negative staining EM. (d) Antibody
responses in mice against (NANP)5 peptide (a-NANP), recombinant CS27IVprotein (a-rCSP), and HBc. (B10.xB10.S) F1 mice were vaccinated with 20 mg
each of low endotoxin (,40 EU/mg protein) preparations of SplitCoreN-CSP149 (Supplementary Fig. S5) or HBc149-NANP CLPs in incomplete Freund’s
adjuvant(IFA) andboosted once 56 dayslater with10 mg antigen inIFA. Antibody responses after thefirst(1
o) andsecond immunization(2
o) were assessed
by ELISA via antiserum dilution series
43; the highest dilution giving a signal at least three-fold above background (pre-immune sera) is indicated.
www.nature.com/scientificreports
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fragments (see Supplementary Fig. S7 online). That construct
encompasses a total mass of ,100 kDa of heterologous sequence
per 15 kDa carrier subunit. We also obtained CLPs by fusing an
attenuated variant of S. aureus enterotoxin B (SEB
45) to GFPb11-
coreC (Supplementary Fig. S7). SEB comprises ,240 aa, and in the
contiguous HBcsystemhad notproduced anysolublefusion protein
(J. Vorreiter, B. Stiles, M. Nassal; unpublished data).
SplitCore is adaptable to the core proteins of other hepad-
naviruses. Preexisting immunity to a carrier might limit repeated
applications via ‘‘carrier induced epitopic suppression’’
46 although
for some HBc-presented antigens there is even evidence for the
opposite
47, 48. Perhaps more important for human vaccines,
tolerance against HBc in chronic HBV carriers could limit immune
enhancement by carrier dependent T cell responses. This may be
circumvented by using core proteins from rodent (woodchuck,
ground squirrel) hepadnaviruses
43 which diverge by ,40% in
their sequences from HBc (see Supplementary Fig. S8a online).
Split woodchuck core protein (SplitWHc) efficiently formed
CLPs, as based on sedimentation, NAGE and EM (see
Supplementary Fig. S8 online), and was able to display full-length
OspA and CSP (not shown). Immunogenicity in mice of the
SplitWHc CSP-CLPs was comparable to that of the respective HBc
CLPs (A. Walker, J. Billaud, M. Nassal, D. Milich; manuscript in
preparation), with generation of very high levels of NANP-specific
and relatively low levels of anti-carrier antibodies (see
Supplementary Fig. 8 online). Furthermore, CLPs formed when
coreN was derived from one and coreC from the other virus
(A. Walker, PhD thesis, University of Freiburg, 2008), consistent
with a substantial sequence tolerance of coreN - coreC association.
Discussion
Genetic insertion of heterologous sequences into surface-exposed
loops of viral capsid proteins provides convenient access to tailored
nanoparticles
4. However, insertion of native proteins nearly always
suffers from structural incompatibility. The SplitCore approach
overcomes this fundamental restriction for HBc, one of the most
attractive carrier scaffolds to date
5, and provides access to particles
with sophisticated surface structures as illustrated in Fig. 6a. The
same concept should be applicable to other protein-based nano-
particles including for, but not limited to, vaccine applications.
To our knowledge, SplitCore is the first truly multimeric split
protein (for a compilation of previously established split protein
systems, see reference
49). Efficient association of the coreN and
coreC fragments may be promoted by the extensive contacts pro-
vided by the a3-a4 hairpin interface (Fig. 1); this should allow for
flexibility regarding choice of the exact splitting site. The insolublity
of either fragment expressed alone (not shown) suggests that the
bicistronic mRNA design also promotes fragment association by
providing spatial proximity during translation. Efficient CLP forma-
tion with various differently structured heterologous proteins
(Figs. 3–5; Supplementary Figs. S2–S7) indicates that many more
willbedisplayableonSplitCoreCLPs,regardlessoftertiarystructure.
Though some restrictions remain, including very large size (exceed-
ing the geometrically restricted space available on the CLP surface),
quaternary structure (e.g. antiparallel dimers, higher order multi-
mers; see
32), or inability of the heterologous protein as such to be
solubly expressed in E. coli (e.g. membrane proteins, glycoproteins),
a multitude of protein antigens remain for vaccine applications.
Particularly useful is the SplitCore-intrinsic ability to generate
opposite surface orientations, allowing to control specificity of the
anti-insert immune response (Fig. 3). If neutralization is not as con-
fined to a specific spatial location as in OspA, mixing CLPs present-
ing the antigen in either orientation provides an easy route to
broaden the anti-insert antibody repertoire.
A point to consider for using HBc as vaccine carrier in humans is
thatanti-HBctestingisuseddiagnosticallytodistinguishHBVinfec-
tion (routinely resulting in a long-lasting anti-HBc response) from
anti-HBV vaccination (with HBs, and thus without inducing
Figure 5 | SplitCore-SplitGFP-GB1: Triple-layer fluorescent particles with exposed targeting domains. (a) Design of SplitCore-splitGFP-GB1 fusions
(SCSGFP-GB1).GB1fusedtooneofthenewendsprovidedbythesplitGFPinsert(seeSupplementaryFig.S3online)shouldyieldfluorescentCLPswith
exposedimmunoglobulinbindingGB1domains.(b)ExpressionandCLPformation.BacteriallysatesweresubjectedtosedimentationasinFig.1c.SDS-
PAGE(top)demonstratedcosedimentationoftwoproteinsoftheexpectedsizesintofractions8to12whichproduceddistinctgreenfluorescentbandsin
NAGE(UV)thatalsostainedwithCB.SimilarresultswereobtainedwithGB1fusedtoGFPb1-10oncoreN(notshown).(c)VisualizationoffoldedGFP
containing material in the gradient tube from which the samples in (b) were derived. (d) Negative staining EM. The two micrographs are from
independent grids onto which material from fraction 8, diluted 10-fold in PBS, was applied. Smaller (*; diameter ,38 nm) and larger (**; diameter
,42 nm) particles were observed. (e,f) SCSGFP-GB1 binds antibodies. (e) Indirect immunofluorescence. Permeabilized HeLa cells were incubated with
mouse anti-tubulin antibody (i, iii) or not (ii, iv), then with SCSGFP-GB1 (i, ii) or an Alexa488-conjugated goat anti-mouse IgG (gam-Alexa488)
antibody (iii,iv).Bothgenerated similar, primaryantibody-dependent stainingpatterns. (f)Fluorescent Westernblot.Decreasing amountsofGFPwere
separated by SDS-PAGE, blotted on nitrocellulose and incubated with a mouse anti-GFP mAb mixture (Roche), then with either gam-Alexa488 or SC-
SGFP-GB1. Fluorescent signals were detected using a Typhoon 7000 imager (GE Healthcare).
www.nature.com/scientificreports
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c/e1 epitope and, on top, sterical shielding by the displayed whole
proteins strongly reduce the anti-HBc response (Fig. 4d and
Supplementary Fig. S8 online); this was also reflected by the much
reduced reactivity of SplitCore CLPs with patient serum anti-HBc
(Supplementary Fig. S1 online). Furthermore, SplitCore CLP-
induced vs. infection-induced anti-HBc antibodies are easily distin-
guished by the absence of any anti-c/e1 response. If considered
necessary, animal HBV based SplitCore CLPs may be used instead
(Supplementary Fig. S8 online). Finally, cross-complementation
between HBc- and WHc-derived coreN and coreC implies that
undesired epitopes may be eliminated via engineered mutations.
Because of its exceptional immunological properties, most pre-
vious efforts towards manipulating HBc were devoted to its use as
a vaccine carrier. However, the SplitCore system also opens new
avenues to nanoparticle design in general. The surface-exposed ter-
mini of SplitCore-displayed heterologous proteins, either on a gen-
uinely extended structure (Xu in Fig. 6b), or on a split insert (split Xf
in Fig. 6b), can be used to build sophisticated multilayer architec-
tures. Just one example are the SC-SGFP-GB1 CLPs, in which the
HBc parts provide the particle scaffold, GFP an easily followable
reporter, and GB1 a specific targeting device. Successful CLP forma-
tion with different proteins much larger than GB1 (Supplementary
Fig.S7)indicatesfewlimitationsforthetargetingdomain.Moreover,
the inner CLP lumen can serve as a cargo container. One example is
CTD mediated packaging of RNA
8 which, in vaccine applications,
canactasaTLR7agonist
50;hencecoreC149vs.coreC183derivatives
may be exploited to modulate the type of immune response induced.
The CTD can be replaced by heterologous sequences (Z in Fig. 5)
of up to ,17 kDa
51, which might themselves have specific function-
alities, including binding of non-nucleic acid and non-peptidic
ligands that could serve as cargo. With appropriate targeting struc-
tures on their surface, such internally modified CLPs could be envi-
saged as specific delivery vehicles.
The SplitCore-intrinsic surface exposure of two accessible new
terminialsoprovidesdistinctadvantagesforenzymaticandchemical
modification. An example is the display of a biotin-acceptor peptide
which can be biotinylated by the E. coli BirA ligase; such CLPs do
indeed specifically interact with streptavidin (see Supplementary
Fig. S9). Many other enzymatic modifications require accessible ter-
mini, amongst them sortase-mediating tagging
52 and N terminal
fatty acylation. According to our preliminary data (T.T.A. Nguyen
and MN) myristoylation via N-myristoyl-transferases can efficiently
be achieved when a suitable substrate sequence is exposed on the
SplitCore CLPs. Chemical conjugation has greatly been advanced by
bioorthogonal ‘‘Click’’ chemistries
53. Site-specific incorporation of
Click-compatible non-natural amino acids into conventional HBc
hasbeenreportedbuttheClickadductswereincompatiblewithCLP
integrity
54, most likely because of sterical strain. Evidently, this
would be overcome by adding the non-natural amino acids to
coreN or coreC.
Various other viral capsid proteins are explored as display scaf-
folds
4 yet up to now the ,400 aa Flock House virus coat protein is
the only one for which native surface display of a complete protein,
the anthrax receptor 2 (ANTRX2), has been achieved by genetic
insertion
55; that protein was chosen because, as in GFP, its termini
fit naturally into surface-exposed loops. Given that the sterical con-
straints for loop insertions are fundamentally similar in any protein,
theadvantagesof thesplit capsidproteinconceptdemonstratedhere
for HBc should as well be applicable to numerous other protein-
based nanoparticle carriers.
Methods
Plasmid constructs. Parental plasmids pET28a2-HBc183H6 and pET28a2-
HBc149H6
32 feature a T7 promoter controlled synthetic HBc gene
56 encoding full-
length (183) or truncated (149) HBV core protein (HBV genotype D, serotype ayw;
accession no.: CAA 24706) with a C terminal His6 tag. SplitCore derivates were
generated by introducing between HBc codons P79 and A80 a stop codon, a second
RBS, and an initiator codon (Fig. 1b); in stop-start vectors the stop codon of coreN
overlappedwiththestartcodonofcoreC(SupplementaryFig.S2c);insomecases,the
cistron order was reversed (Supplementary Fig. S7e). All constructs were generated
using standard PCR methods and verified by DNA sequencing.
Insert protein coding sequences. Plasmids used as sources for the genes of GFP
22,
OspA
28 and OspCa
24 have previously been described. For CSP, plasmid pDS56-32/
RBSII-CS27iVC_6XHis
42 was obtained from the Malaria Research and Reference
Reagent resource (MR4; code MRA-272). A plasmid encoding genetically attenuated
Figure 6 | Summary of unique SplitCore features. (a) Graphical illustration of representative, increasingly complex SplitCore CLPs generated in this
study.Thestructuralmodelsofeachproteinaredrawnapproximatelytoscale;heterologousmoleculesfusedtothesecondsubunitperHBcdimer(grey)
havebeen omittedforclarity. Thecross-sections shownare hypothetical andonlyserve toillustrative pertinentSplitCore features.Splitting theinsertion
loop in HBc (left) leaves two surface-accessible termini (in red) for fusion of heterologous proteins regardless of their 3D structure. A protein witha
favorable structure for insertion, such as GFP (middle), may itself be split to provide new exposed termini, to which an additional protein, such as OspA
(right), can be added. The accessible termini on SplitCore, or the second or third layer proteins, are as well available for other types of modification.
(b)SchematiccomparisonoftheconventionalcontiguouschainHBcvs.SplitCoreplatforms.Thehalf-hexagonsymbolizestheicosahedralparticleshell.
InconventionalHBc(left)surfacepresentationbyc/e1insertionofforeignproteinligandsXisrestrictedtothefewhavinganaturallyfavorablestructure
(Xf). The CLP lumen may be modulated by C terminal modifications; the authentic CTD packages RNA as cargo but may be replaced, within limits
(,17 kDa
51), by heterologous moieties (Z) that could act as cargo or provide specific functions (ligand binding, reporter probes). In SplitCore the new
exposed termini allow (i) presentation of unfavorably structured inserts (Xu) in either orientation; of Xf ligands with comparable efficiency as in the
contiguoussystem(ii);andoftwoligandspercarriersubunit(iii).Solvent-exposedterminiofXuligandsmaydirectlybeusedasfurtherattachmentsites
(not tested); however, as demonstrated, this is definitely possible for a split Xf ligand like GFP. Particle-internal features can be manipulated as in
contiguous chain HBc. One out of various applications are CLPs carrying a targeting ligand (Y1, Y2), a monitoring reporter (split X), plus a cargo
specified by Z.
www.nature.com/scientificreports
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45) was kindly provided
by Dr. B. Stiles.
Junctionsequencesinindividualconstructs.ThelinkersconnectingcoreNorcoreC
with the inserts were typically G4SorG 4T.Inthe SplitCore OspA fusions the original
linkers ((G4S)2;( G 4S)2RG4DLLG4)) from the contiguous construct
28 were
maintainedforcomparability.SplitGFPwasbasedonasolubilityenhancedversion
44;
theNterminalpartconsistedofGFPaa1–214(GFPb1-10),followedbythedipeptide
DP; GFPb11 contained the sequence 214–238, preceded by an artificial initiator
codon.
Protein Expression and Purification. E. coli BL21(DE3) Codonplus cells
(Stratagene) wereused throughout as described
24, 29, 32.Conditions for sedimentation
through10–60%sucrosestepgradientsat20uCwereasfollows,dependingonsample
volume:SW28rotor,3:45 hat28,000 rpm
24;TST41.14rotor2 hat41,000 rpm;TLS-
55rotor,45 minat55,000 rpm.Gradientswereharvestedin14fractions(2.6 mleach
forSW28;860mleachforTST41.14;100mleachforTLS-55)fromthetop.Forfurther
purification, the pooled center gradient fractions were dialysed against TN150 buffer
(25 mM Tris-Cl [pH7.5], 150 mM NaCl) and subjected to a second gradient
sedimentation or size exclusion chromatography on Superose 6 (GE Healthcare).
Endotoxin depletion. Endotoxin was depleted by phase separation with Triton
X-114essentially as described
36.Residual detergent wasdepleted byrepeated dialysis
against excess PBS at 4uC. Endotoxin contents dropped from 10
5–10
6 EU/mg protein
in the crude lysates to below 50 EU/mg, as determined by the Pyrochrome Assay
(Associates of Cape Cod, Inc., MA).
Native agarose gel electrophoresis (NAGE) and immunoblotting. NAGE was
performed in 1% agarose gels (2.6% for T53 vs. T54 particle distinction;
SupplementaryFig.S1a)asdescribed
8.Forimmunologicaldetection,NAGEorSDS-
PAGE gels were blotted to PVDF membranes which were probed with specific
primary antibodies and peroxidase-conjugated secondary antibodies plus
chemiluminescent substrates
29. Monoclonal anti-HBc antibodies used were
10E11 and 10F10 (anti-coreN and anti-coreC, respectively
57); 312 and 3105
(anti-c/e1
13, 58, 59); 275
13 and 3120
35, both recognizing particle-specific epitopes.
Electron Microscopy. Negative staining EM using 2% uranyl acetate was performed
as described
34.
Immunoglobulin binding by SC-SGFP-GB1 CLPs. For indirect
immunofluorescence, 4% paraformaldehyde fixed HeLa cells were permeabilized
using 0.2 % Triton X-100 in PBS, blocked with 5% BSA in PBS and incubated with
0.05 mg/ml of mouse-anti-tubulin mAb, or not; for detection, either 0.13 mM goat-
anti-mouse IgG antibody conjugated to Alexa488 (gam-Alexa488; Invitrogen) or
0.05mM SC-SGFP-GB1 CLPs were used. Images weretakenwith a Zeiss AxioVert35
microscope. For fluorescent Western blot detection, a dilution series of recombinant
GFP mixed with constant amounts (1 mg/lane) each of BSA and HBc149H6 was
separated by SDS-PAGE and electroblotted to nitrocellulose membranes. After
blocking, the blots were incubated with mouse-anti-GFP mAb (Roche), then with
either2.0mg/mlgam-Alexa488or2.5mg/mlSC-SGFP-GB1CLPs.Fluorescentsignals
were recorded using a Typhoon 7000 imager (GE Healthcare).
Details of the evaluation of the reactivity of SplitCore CLPs with human anti-HBc
in commercial ELISAs and the immunizations with OspA- and CSP-presenting
SplitCore CLPs are given in the Supplementary Protocols.
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